View Future GrowthTrivarX 過去の業績過去 基準チェック /06TrivarXは19.6%の年平均成長率で業績を伸ばしているが、Healthcare Services業界はgrowingで20.5%毎年増加している。売上は減少しており、年平均9.2%の割合である。主要情報19.59%収益成長率36.99%EPS成長率Healthcare Services 業界の成長1.72%収益成長率-9.22%株主資本利益率-8.96%ネット・マージン2,213.15%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australiaお知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australiaお知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listingお知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australiaお知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.収支内訳TrivarX の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:MDBI.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 250-21030 Sep 250-21030 Jun 251-11031 Mar 252-11031 Dec 24201030 Sep 241-11030 Jun 241-11031 Mar 240-31031 Dec 230-41030 Sep 230-31030 Jun 231-31031 Mar 231-81131 Dec 221-121130 Sep 221-131130 Jun 221-131131 Mar 221-71131 Dec 211-11030 Sep 211-11030 Jun 211-11031 Mar 211-21031 Dec 201-21030 Sep 201-31030 Jun 201-42031 Mar 201-42031 Dec 191-52130 Sep 193-63130 Jun 194-75031 Mar 193-116131 Dec 183-158230 Sep 183-157330 Jun 182-167331 Mar 183-155531 Dec 173-134630 Sep 173-113530 Jun 173-102431 Mar 173-92331 Dec 164-71230 Sep 163-71230 Jun 162-61231 Mar 162-61131 Dec 151-70030 Sep 151-70030 Jun 150-800質の高い収益: MDBI.Fは現在利益が出ていません。利益率の向上: MDBI.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MDBI.Fは利益を出していないが、過去 5 年間で年間19.6%の割合で損失を削減してきた。成長の加速: MDBI.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MDBI.Fは利益が出ていないため、過去 1 年間の収益成長をHealthcare Services業界 ( 4.2% ) と比較することは困難です。株主資本利益率高いROE: MDBI.Fは現在利益が出ていないため、自己資本利益率 ( -8.96% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:05終値2026/05/06 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TrivarX Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stuart RobertsPitt Street Research Pty Ltd.
お知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia
お知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia
お知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.
お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia
お知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.